

HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 1 – Induction of Suboxone (Buprenorphine/Naloxone), by Site

	Heng County China	Nanning China	Xinjiang China	Chiang Mai Thailand	Total
Number Enrolled	411	161	478	202	1252
Long Term Medication Assisted Treatment	205	79	239	101	624
Short Term Medication Assisted Treatment	206	82	239	101	628
Induction					
Initial Induction	411/411 (100%)	161/161 (100%)	478/478 (100%)	202/202 (100%)	1252/1252 (100%)
Completed 3 Days	377/411 (92%)	135/161 (84%)	411/478 (86%)	197/202 (98%)	1120/1252 (89%)
< 3 Days	34/411 (8%)	26/161 (16%)	67/478 (14%)	5/202 (2%)	132/1252 (11%)
Second Induction	106/411 (26%)	54/161 (34%)	183/478 (38%)	43/202 (21%)	386/1252 (31%)
Three or More Inductions ¹	13/205 (6%)	2/79 (3%)	31/239 (13%)	7/101 (7%)	53/624 (8%)
Initial Induction Summary					
Total Dose (mg)					
Day 1					
0 – 8	407/411 (99%)	144/161 (89%)	436/478 (91%)	179/202 (89%)	1166/1252 (93%)
9 – 16	4/411 (1%)	16/161 (10%)	42/478 (9%)	23/202 (11%)	85/1252 (7%)
Day 2					
0 – 8	43/411 (10%)	5/161 (3%)	25/478 (5%)	21/202 (10%)	94/1252 (8%)
9 – 16	348/411 (85%)	136/161 (84%)	405/478 (85%)	158/202 (78%)	1047/1252 (84%)
17 – 24 ²	1/411 (<1%)	1/161 (1%)	0/478 (0%)	6/202 (3%)	8/1252 (1%)
25 – 32 ²	0/411 (0%)	0/161 (0%)	0/478 (0%)	13/202 (6%)	13/1252 (1%)
Day 3					
0 – 8	29/411 (7%)	3/161 (2%)	17/478 (4%)	15/202 (7%)	64/1252 (5%)
9 – 16	256/411 (62%)	51/161 (32%)	103/478 (22%)	134/202 (66%)	544/1252 (43%)
17 – 24	101/411 (25%)	86/161 (53%)	273/478 (57%)	30/202 (15%)	490/1252 (39%)
25 – 32	1/411 (<1%)	2/161 (1%)	42/478 (9%)	18/202 (9%)	63/1252 (5%)

¹ Applies only for the Long Term Medication Assisted Treatment.

² For protocol version 1.0, the maximum daily dose allowed after the first day of induction is 32 mg. In protocol version 2.0, most participants are expected to receive up to 16 mg on day 2.

HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 1 – Induction of Suboxone (Buprenorphine/Naloxone), by Site

	Heng County China	Nanning China	Xinjiang China	Chiang Mai Thailand	Total
# of Doses Given					
Day 1					
1	36/411 (9%)	6/161 (4%)	34/478 (7%)	9/202 (4%)	85/1252 (7%)
2	372/411 (91%)	144/161 (89%)	405/478 (85%)	170/202 (84%)	1091/1252 (87%)
3	3/411 (1%)	10/161 (6%)	39/478 (8%)	11/202 (5%)	63/1252 (5%)
4	0/411 (0%)	0/161 (0%)	0/478 (0%)	12/202 (6%)	12/1252 (1%)
Day 2					
1	254/411 (62%)	59/161 (37%)	136/478 (28%)	141/202 (70%)	590/1252 (47%)
2	138/411 (34%)	83/161 (52%)	293/478 (61%)	39/202 (19%)	553/1252 (44%)
3	0/411 (0%)	0/161 (0%)	1/478 (<1%)	9/202 (4%)	10/1252 (1%)
4	0/411 (0%)	0/161 (0%)	0/478 (0%)	9/202 (4%)	9/1252 (1%)
Day 3					
1	355/411 (86%)	119/161 (74%)	220/478 (46%)	186/202 (92%)	880/1252 (70%)
2	32/411 (8%)	22/161 (14%)	168/478 (35%)	10/202 (5%)	232/1252 (19%)
3	0/411 (0%)	1/161 (1%)	44/478 (9%)	1/202 (<1%)	46/1252 (4%)
4	0/411 (0%)	0/161 (0%)	3/478 (1%)	0/202 (0%)	3/1252 (<1%)
First Morning COWS					
Day 1					
Mean (SD)	10 (1.8)	10 (1.6)	10 (1.6)	11 (3.1)	10 (2.0)
Median	9	9	10	10	10
Min, Max	8, 18	8, 15	8, 16	8, 25	8, 25
25th, 75th percentile	9, 11	8, 11	9, 11	8, 12	9, 11
Day 2					
Mean (SD)	5 (2.0)	5 (2.6)	6 (2.7)	4 (2.7)	5 (2.6)
Median	4	5	6	4	5
Min, Max	0, 14	0, 15	0, 18	0, 19	0, 19
25th, 75th percentile	3, 6	4, 7	4, 8	3, 5	4, 7
Day 3					
Mean (SD)	3 (2.2)	5 (2.5)	5 (2.6)	3 (2.2)	4 (2.6)
Median	3	5	5	3	4
Min, Max	0, 20	0, 12	0, 19	0, 10	0, 20
25th, 75th percentile	1, 4	3, 6	4, 7	1, 4	2, 6

¹ Applies only for the Long Term Medication Assisted Treatment.

² For protocol version 1.0, the maximum daily dose allowed after the first day of induction is 32 mg. In protocol version 2.0, most participants are expected to receive up to 16 mg on day 2.

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 1 – Induction of Suboxone (Buprenorphine/Naloxone), by Site**

	Heng County China	Nanning China	Xinjiang China	Chiang Mai Thailand	Total
Second Induction Summary					
Total Dose (mg)					
Day 1					
0 – 8	106/106 (100%)	51/54 (94%)	177/183 (97%)	41/43 (95%)	375/386 (97%)
9 – 16	0/106 (0%)	3/54 (6%)	6/183 (3%)	2/43 (5%)	11/386 (3%)
Day 2					
0 – 8	14/106 (13%)	1/54 (2%)	41/183 (22%)	5/43 (12%)	61/386 (16%)
9 – 16	80/106 (75%)	50/54 (93%)	121/183 (66%)	34/43 (79%)	285/386 (74%)
17 – 24 ²	0/106 (0%)	0/54 (0%)	0/183 (0%)	2/43 (5%)	2/386 (1%)
25 – 32 ²	0/106 (0%)	0/54 (0%)	0/183 (0%)	0/43 (0%)	0/386 (0%)
Day 3					
0 – 8	12/106 (11%)	2/54 (4%)	26/183 (14%)	3/43 (7%)	43/386 (11%)
9 – 16	66/106 (62%)	13/54 (24%)	60/183 (33%)	26/43 (60%)	165/386 (43%)
17 – 24	18/106 (17%)	36/54 (67%)	55/183 (30%)	8/43 (19%)	117/386 (30%)
25 – 32	0/106 (0%)	0/54 (0%)	5/183 (3%)	0/43 (0%)	5/386 (1%)
# of Doses Given					
Day 1					
1	18/106 (17%)	2/54 (4%)	57/183 (31%)	3/43 (7%)	80/386 (21%)
2	88/106 (83%)	50/54 (93%)	120/183 (66%)	38/43 (88%)	296/386 (77%)
3	0/106 (0%)	2/54 (4%)	6/183 (3%)	2/43 (5%)	10/386 (3%)
4	0/106 (0%)	0/54 (0%)	0/183 (0%)	0/43 (0%)	0/386 (0%)
Day 2					
1	70/106 (66%)	14/54 (26%)	92/183 (50%)	30/43 (70%)	206/386 (53%)
2	24/106 (23%)	37/54 (69%)	67/183 (37%)	11/43 (26%)	139/386 (36%)
3	0/106 (0%)	0/54 (0%)	3/183 (2%)	0/43 (0%)	3/386 (1%)
4	0/106 (0%)	0/54 (0%)	0/183 (0%)	0/43 (0%)	0/386 (0%)
Day 3					
1	92/106 (87%)	42/54 (78%)	103/183 (56%)	35/43 (81%)	272/386 (70%)
2	4/106 (4%)	8/54 (15%)	38/183 (21%)	2/43 (5%)	52/386 (13%)
3	0/106 (0%)	1/54 (2%)	4/183 (2%)	0/43 (0%)	5/386 (1%)
4	0/106 (0%)	0/54 (0%)	1/183 (1%)	0/43 (0%)	1/386 (<1%)

¹ Applies only for the Long Term Medication Assisted Treatment.

² For protocol version 1.0, the maximum daily dose allowed after the first day of induction is 32 mg. In protocol version 2.0, most participants are expected to receive up to 16 mg on day 2.

HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 1 – Induction of Suboxone (Buprenorphine/Naloxone), by Site

	Heng County China	Nanning China	Xinjiang China	Chiang Mai Thailand	Total
First Morning COWS					
Day 1					
Mean (SD)	9 (1.5)	10 (2.1)	9 (2.0)	9 (1.8)	9 (1.9)
Median	9	10	9	9	9
Min, Max	4, 14	8, 18	0, 15	6, 15	0, 18
25th, 75th percentile	8, 10	9, 11	8, 10	8, 10	8, 10
Day 2					
Mean (SD)	4 (1.9)	7 (3.1)	6 (2.7)	5 (2.5)	5 (2.6)
Median	4	6	6	4	5
Min, Max	0, 10	0, 13	0, 11	0, 11	0, 13
25th, 75th percentile	3, 5	4, 9	4, 8	3, 6	3, 7
Day 3					
Mean (SD)	2 (1.8)	5 (2.8)	5 (2.9)	3 (1.4)	4 (2.7)
Median	3	5	5	3	4
Min, Max	0, 8	0, 13	0, 12	1, 7	0, 13
25th, 75th percentile	1, 4	4, 7	3, 7	2, 4	2, 6

¹ Applies only for the Long Term Medication Assisted Treatment.

² For protocol version 1.0, the maximum daily dose allowed after the first day of induction is 32 mg. In protocol version 2.0, most participants are expected to receive up to 16 mg on day 2.

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2a1 – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Heng County, China
Long Term Medication Assisted Treatment**

	Weeks Since Induction								
	Weeks 1–4	Weeks 5–8	Weeks 9–12	Weeks 13–16	Weeks 17–20	Weeks 21–24	Weeks 25–28	Weeks 29–32	Weeks 33–36
N Expected	205	205	205	205	204	204	204	204	203
Missing [1]	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Evaluated	205 (100%)	205 (100%)	205 (100%)	205 (100%)	204 (100%)	204 (100%)	204 (100%)	204 (100%)	203 (100%)
Re-induction [2]	4/205 (2%)	3/205 (1%)	9/205 (4%)	4/205 (2%)	5/204 (2%)	13/204 (6%)	6/204 (3%)	8/204 (4%)	5/203 (2%)
Termination [3]	0/205 (0%)	0/205 (0%)	0/205 (0%)	1/205 (<1%)	0/204 (0%)	0/204 (0%)	0/204 (0%)	1/204 (<1%)	0/203 (0%)
Monthly Dosing [2][3]									
Dosing = 0%	6/205 (3%)	17/205 (8%)	38/205 (19%)	56/205 (27%)	65/204 (32%)	58/204 (28%)	61/204 (30%)	76/204 (37%)	84/203 (41%)
Dosing >= 25%	191/205 (93%)	183/205 (89%)	162/205 (79%)	144/205 (70%)	137/204 (67%)	143/204 (70%)	134/204 (66%)	123/204 (60%)	113/203 (56%)
Dosing >= 50%	181/205 (88%)	170/205 (83%)	150/205 (73%)	133/205 (65%)	129/204 (63%)	134/204 (66%)	124/204 (61%)	118/204 (58%)	111/203 (55%)
Dosing >= 75%	173/205 (84%)	149/205 (73%)	136/205 (66%)	115/205 (56%)	115/204 (56%)	117/204 (57%)	109/204 (53%)	101/204 (50%)	102/203 (50%)
Dosing = 100%	126/205 (61%)	97/205 (47%)	82/205 (40%)	75/205 (37%)	67/204 (33%)	79/204 (39%)	64/204 (31%)	64/204 (31%)	65/203 (32%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100
Cumulative Dosing									
Dosing = 0%	6/205 (3%)	6/205 (3%)	6/205 (3%)	6/205 (3%)	6/204 (3%)	5/204 (2%)	5/204 (2%)	5/204 (2%)	5/203 (2%)
Dosing >= 25%	191/205 (93%)	188/205 (92%)	184/205 (90%)	181/205 (88%)	176/204 (86%)	173/204 (85%)	172/204 (84%)	169/204 (83%)	163/203 (80%)
Dosing >= 50%	181/205 (88%)	179/205 (87%)	169/205 (82%)	160/205 (78%)	148/204 (73%)	141/204 (69%)	140/204 (69%)	139/204 (68%)	136/203 (67%)
Dosing >= 75%	173/205 (84%)	155/205 (76%)	144/205 (70%)	131/205 (64%)	128/204 (63%)	122/204 (60%)	116/204 (57%)	111/204 (54%)	103/203 (51%)
Dosing = 100%	126/205 (61%)	81/205 (40%)	63/205 (31%)	48/205 (23%)	37/204 (18%)	29/204 (14%)	24/204 (12%)	18/204 (9%)	16/203 (8%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100
Average Daily Dose (mg) for Days with Drug Coverage									
N	199	188	167	149	139	146	143	128	119
Mean (SD)	14 (3.2)	13 (2.9)	13 (2.8)	12 (2.7)	12 (2.9)	12 (2.8)	11 (3.0)	11 (3.0)	11 (2.8)
Median	15	14	12	12	12	12	12	12	12
Min, Max	4, 24	4, 20	4, 17	4, 17	4, 18	4, 16	5, 18	4, 16	4, 16
Q1, Q3	12, 16	12, 16	10, 16	10, 14	10, 14	10, 14	8, 14	8, 14	8, 12

[1] Participants are considered as missing if all CRFs of the 4-week period were not received.

[2] Percentages of dosing for the participants who were re-induced are based on the remainder number of days after induction in that period.

[3] Percentages of dosing for the participants who were terminated early are calculated up to the day before termination in that period.

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2a1 – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Heng County, China
Long Term Medication Assisted Treatment**

	Weeks Since Induction		
	Weeks 37–40	Weeks 41–44	Weeks 45–48
N Expected	203	203	200
Missing [1]	0 (0%)	0 (0%)	0 (0%)
Evaluated	203 (100%)	203 (100%)	200 (100%)
Re-induction [2]	8/203 (4%)	10/203 (5%)	2/200 (1%)
Termination [3]	0/203 (0%)	3/203 (1%)	6/200 (3%)
Monthly Dosing [2][3]			
Dosing = 0%	86/203 (42%)	84/203 (41%)	96/200 (48%)
Dosing >= 25%	115/203 (57%)	113/203 (56%)	102/200 (51%)
Dosing >= 50%	107/203 (53%)	106/203 (52%)	96/200 (48%)
Dosing >= 75%	98/203 (48%)	98/203 (48%)	84/200 (42%)
Dosing = 100%	63/203 (31%)	61/203 (30%)	55/200 (28%)
Min, Max	0, 100	0, 100	0, 100
Cumulative Dosing			
Dosing = 0%	5/203 (2%)	5/203 (2%)	5/200 (3%)
Dosing >= 25%	159/203 (78%)	155/203 (76%)	152/200 (76%)
Dosing >= 50%	133/203 (66%)	129/203 (64%)	125/200 (63%)
Dosing >= 75%	101/203 (50%)	96/203 (47%)	92/200 (46%)
Dosing = 100%	9/203 (4%)	8/203 (4%)	7/200 (4%)
Min, Max	0, 100	0, 100	0, 100
Average Daily Dose (mg) for Days with Drug Coverage			
N	117	119	104
Mean (SD)	10 (2.8)	10 (3.1)	9 (2.8)
Median	10	10	9
Min, Max	4, 17	3, 16	2, 15
Q1, Q3	8, 12	8, 12	7, 11
[1] Participants are considered as missing if all CRFs of the 4-week period were not received.			
[2] Percentages of dosing for the participants who were re-induced are based on the remainder number of days after induction in that period.			
[3] Percentages of dosing for the participants who were terminated early are calculated up to the day before termination in that period.			

HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2a2 – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Nanning, China
Long Term Medication Assisted Treatment

	Weeks Since Induction								
	Weeks 1–4	Weeks 5–8	Weeks 9–12	Weeks 13–16	Weeks 17–20	Weeks 21–24	Weeks 25–28	Weeks 29–32	Weeks 33–36
N Expected	79	79	79	79	79	79	79	79	79
Missing [1]	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Evaluated	79 (100%)	79 (100%)	79 (100%)	79 (100%)	79 (100%)	79 (100%)	79 (100%)	79 (100%)	79 (100%)
Re-induction [2]	0/79 (0%)	1/79 (1%)	3/79 (4%)	0/79 (0%)	1/79 (1%)	4/79 (5%)	3/79 (4%)	1/79 (1%)	1/79 (1%)
Termination [3]	0/79 (0%)	0/79 (0%)	0/79 (0%)	0/79 (0%)	0/79 (0%)	0/79 (0%)	0/79 (0%)	0/79 (0%)	0/79 (0%)
Monthly Dosing [2][3]									
Dosing = 0%	8/79 (10%)	11/79 (14%)	14/79 (18%)	19/79 (24%)	22/79 (28%)	23/79 (29%)	25/79 (32%)	31/79 (39%)	34/79 (43%)
Dosing >= 25%	70/79 (89%)	67/79 (85%)	63/79 (80%)	59/79 (75%)	56/79 (71%)	55/79 (70%)	53/79 (67%)	47/79 (59%)	44/79 (56%)
Dosing >= 50%	69/79 (87%)	62/79 (78%)	61/79 (77%)	58/79 (73%)	54/79 (68%)	54/79 (68%)	49/79 (62%)	46/79 (58%)	44/79 (56%)
Dosing >= 75%	66/79 (84%)	61/79 (77%)	57/79 (72%)	56/79 (71%)	51/79 (65%)	50/79 (63%)	44/79 (56%)	42/79 (53%)	41/79 (52%)
Dosing = 100%	56/79 (71%)	41/79 (52%)	44/79 (56%)	43/79 (54%)	36/79 (46%)	39/79 (49%)	28/79 (35%)	30/79 (38%)	29/79 (37%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100
Cumulative Dosing									
Dosing = 0%	8/79 (10%)	7/79 (9%)	7/79 (9%)	7/79 (9%)	7/79 (9%)	7/79 (9%)	7/79 (9%)	7/79 (9%)	7/79 (9%)
Dosing >= 25%	70/79 (89%)	70/79 (89%)	68/79 (86%)	65/79 (82%)	64/79 (81%)	63/79 (80%)	63/79 (80%)	63/79 (80%)	61/79 (77%)
Dosing >= 50%	69/79 (87%)	65/79 (82%)	63/79 (80%)	63/79 (80%)	61/79 (77%)	58/79 (73%)	57/79 (72%)	56/79 (71%)	56/79 (71%)
Dosing >= 75%	66/79 (84%)	61/79 (77%)	61/79 (77%)	58/79 (73%)	55/79 (70%)	54/79 (68%)	51/79 (65%)	50/79 (63%)	46/79 (58%)
Dosing = 100%	56/79 (71%)	41/79 (52%)	38/79 (48%)	31/79 (39%)	26/79 (33%)	23/79 (29%)	18/79 (23%)	15/79 (19%)	13/79 (16%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100
Average Daily Dose (mg) for Days with Drug Coverage									
N	71	68	65	60	57	56	54	48	45
Mean (SD)	17 (3.8)	15 (2.9)	14 (3.5)	13 (3.6)	13 (3.6)	13 (3.9)	13 (4.1)	12 (4.1)	13 (3.4)
Median	18	16	16	16	15	14	15	13	12
Min, Max	2, 23	1, 20	1, 18	1, 16	2, 16	2, 21	2, 20	2, 16	4, 16
Q1, Q3	17, 20	14, 16	12, 16	10, 16	11, 16	10, 16	10, 16	10, 16	10, 16

[1] Participants are considered as missing if all CRFs of the 4-week period were not received.

[2] Percentages of dosing for the participants who were re-induced are based on the remainder number of days after induction in that period.

[3] Percentages of dosing for the participants who were terminated early are calculated up to the day before termination in that period.

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2a2 – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Nanning, China
Long Term Medication Assisted Treatment**

	Weeks Since Induction		
	Weeks 37–40	Weeks 41–44	Weeks 45–48
N Expected	79	78	77
Missing [1]	0 (0%)	0 (0%)	0 (0%)
Evaluated	79 (100%)	78 (100%)	77 (100%)
Re-induction [2]	1/79 (1%)	2/78 (3%)	1/77 (1%)
Termination [3]	1/79 (1%)	1/78 (1%)	3/77 (4%)
Monthly Dosing [2][3]			
Dosing = 0%	34/79 (43%)	33/78 (42%)	36/77 (47%)
Dosing >= 25%	45/79 (57%)	45/78 (58%)	38/77 (49%)
Dosing >= 50%	45/79 (57%)	42/78 (54%)	37/77 (48%)
Dosing >= 75%	42/79 (53%)	39/78 (50%)	33/77 (43%)
Dosing = 100%	21/79 (27%)	22/78 (28%)	19/77 (25%)
Min, Max	0, 100	0, 100	0, 100
Cumulative Dosing			
Dosing = 0%	7/79 (9%)	6/78 (8%)	5/77 (6%)
Dosing >= 25%	60/79 (76%)	59/78 (76%)	58/77 (75%)
Dosing >= 50%	55/79 (70%)	55/78 (71%)	50/77 (65%)
Dosing >= 75%	44/79 (56%)	44/78 (56%)	43/77 (56%)
Dosing = 100%	9/79 (11%)	8/78 (10%)	5/77 (6%)
Min, Max	0, 100	0, 100	0, 100
Average Daily Dose (mg) for Days with Drug Coverage			
N	45	45	41
Mean (SD)	13 (3.5)	13 (3.4)	11 (3.3)
Median	12	13	11
Min, Max	5, 23	5, 20	1, 16
Q1, Q3	12, 16	12, 16	9, 13
[1] Participants are considered as missing if all CRFs of the 4-week period were not received.			
[2] Percentages of dosing for the participants who were re-induced are based on the remainder number of days after induction in that period.			
[3] Percentages of dosing for the participants who were terminated early are calculated up to the day before termination in that period.			

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2a3 – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Xinjiang, China
Long Term Medication Assisted Treatment**

	Weeks Since Induction								
	Weeks 1–4	Weeks 5–8	Weeks 9–12	Weeks 13–16	Weeks 17–20	Weeks 21–24	Weeks 25–28	Weeks 29–32	Weeks 33–36
N Expected	239	239	239	239	239	238	238	238	238
Missing [1]	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Evaluated	239 (100%)	239 (100%)	239 (100%)	239 (100%)	239 (100%)	238 (100%)	238 (100%)	238 (100%)	238 (100%)
Re-induction [2]	2/239 (1%)	6/239 (3%)	11/239 (5%)	9/239 (4%)	17/239 (7%)	24/238 (10%)	17/238 (7%)	26/238 (11%)	7/238 (3%)
Termination [3]	0/239 (0%)	0/239 (0%)	0/239 (0%)	0/239 (0%)	1/239 (<1%)	0/238 (0%)	0/238 (0%)	0/238 (0%)	0/238 (0%)
Monthly Dosing [2][3]									
Dosing = 0%	9/239 (4%)	23/239 (10%)	49/239 (21%)	60/239 (25%)	75/239 (31%)	76/238 (32%)	83/238 (35%)	88/238 (37%)	96/238 (40%)
Dosing >= 25%	221/239 (92%)	199/239 (83%)	181/239 (76%)	169/239 (71%)	154/239 (64%)	152/238 (64%)	147/238 (62%)	141/238 (59%)	137/238 (58%)
Dosing >= 50%	207/239 (87%)	180/239 (75%)	162/239 (68%)	145/239 (61%)	142/239 (59%)	132/238 (55%)	133/238 (56%)	123/238 (52%)	124/238 (52%)
Dosing >= 75%	190/239 (79%)	157/239 (66%)	141/239 (59%)	119/239 (50%)	109/239 (46%)	115/238 (48%)	107/238 (45%)	108/238 (45%)	103/238 (43%)
Dosing = 100%	118/239 (49%)	84/239 (35%)	67/239 (28%)	63/239 (26%)	51/239 (21%)	54/238 (23%)	52/238 (22%)	56/238 (24%)	50/238 (21%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100
Cumulative Dosing									
Dosing = 0%	9/239 (4%)	8/239 (3%)	8/239 (3%)	7/239 (3%)	6/239 (3%)	5/238 (2%)	5/238 (2%)	4/238 (2%)	4/238 (2%)
Dosing >= 25%	221/239 (92%)	216/239 (90%)	211/239 (88%)	203/239 (85%)	199/239 (83%)	191/238 (80%)	188/238 (79%)	187/238 (79%)	187/238 (79%)
Dosing >= 50%	207/239 (87%)	192/239 (80%)	183/239 (77%)	177/239 (74%)	163/239 (68%)	156/238 (66%)	152/238 (64%)	150/238 (63%)	145/238 (61%)
Dosing >= 75%	190/239 (79%)	162/239 (68%)	147/239 (62%)	131/239 (55%)	121/239 (51%)	112/238 (47%)	108/238 (45%)	101/238 (42%)	99/238 (42%)
Dosing = 100%	118/239 (49%)	73/239 (31%)	43/239 (18%)	27/239 (11%)	18/239 (8%)	17/238 (7%)	11/238 (5%)	9/238 (4%)	9/238 (4%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100
Average Daily Dose (mg) for Days with Drug Coverage									
N	230	216	190	179	164	162	155	150	142
Mean (SD)	18 (4.4)	14 (3.6)	12 (3.9)	12 (4.0)	11 (4.4)	11 (4.4)	11 (3.8)	11 (4.7)	11 (4.5)
Median	18	15	13	12	12	11	11	11	10
Min, Max	2, 32	2, 32	2, 26	2, 28	1, 25	1, 25	1, 20	2, 26	2, 24
Q1, Q3	16, 20	11, 16	10, 15	9, 15	8, 14	8, 14	8, 14	7, 14	7, 14

[1] Participants are considered as missing if all CRFs of the 4-week period were not received.

[2] Percentages of dosing for the participants who were re-induced are based on the remainder number of days after induction in that period.

[3] Percentages of dosing for the participants who were terminated early are calculated up to the day before termination in that period.

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2a3 – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Xinjiang, China
Long Term Medication Assisted Treatment**

	Weeks Since Induction		
	Weeks 37–40	Weeks 41–44	Weeks 45–48
N Expected	238	237	234
Missing [1]	0 (0%)	0 (0%)	0 (0%)
Evaluated	238 (100%)	237 (100%)	234 (100%)
Re-induction [2]	11/238 (5%)	16/237 (7%)	4/234 (2%)
Termination [3]	1/238 (<1%)	3/237 (1%)	6/234 (3%)
Monthly Dosing [2][3]			
Dosing = 0%	105/238 (44%)	105/237 (44%)	116/234 (50%)
Dosing >= 25%	126/238 (53%)	125/237 (53%)	110/234 (47%)
Dosing >= 50%	116/238 (49%)	107/237 (45%)	97/234 (41%)
Dosing >= 75%	99/238 (42%)	92/237 (39%)	80/234 (34%)
Dosing = 100%	48/238 (20%)	45/237 (19%)	40/234 (17%)
Min, Max	0, 100	0, 100	0, 100
Cumulative Dosing			
Dosing = 0%	4/238 (2%)	4/237 (2%)	4/234 (2%)
Dosing >= 25%	184/238 (77%)	180/237 (76%)	176/234 (75%)
Dosing >= 50%	139/238 (58%)	132/237 (56%)	123/234 (53%)
Dosing >= 75%	96/238 (40%)	93/237 (39%)	88/234 (38%)
Dosing = 100%	8/238 (3%)	6/237 (3%)	5/234 (2%)
Min, Max	0, 100	0, 100	0, 100
Average Daily Dose (mg) for Days with Drug Coverage			
N	133	132	118
Mean (SD)	10 (4.5)	10 (5.0)	9 (4.5)
Median	11	11	9
Min, Max	2, 17	1, 32	2, 28
Q1, Q3	7, 15	6, 14	5, 12
[1] Participants are considered as missing if all CRFs of the 4-week period were not received.			
[2] Percentages of dosing for the participants who were re-induced are based on the remainder number of days after induction in that period.			
[3] Percentages of dosing for the participants who were terminated early are calculated up to the day before termination in that period.			

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2a4 – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Chiang Mai, Thailand
Long Term Medication Assisted Treatment**

	Weeks Since Induction								
	Weeks 1–4	Weeks 5–8	Weeks 9–12	Weeks 13–16	Weeks 17–20	Weeks 21–24	Weeks 25–28	Weeks 29–32	Weeks 33–36
N Expected	101	101	101	101	101	101	101	101	101
Missing [1]	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Evaluated	101 (100%)	101 (100%)	101 (100%)	101 (100%)	101 (100%)	101 (100%)	101 (100%)	101 (100%)	101 (100%)
Re-induction [2]	2/101 (2%)	5/101 (5%)	2/101 (2%)	3/101 (3%)	1/101 (1%)	3/101 (3%)	0/101 (0%)	4/101 (4%)	3/101 (3%)
Termination [3]	0/101 (0%)	0/101 (0%)	0/101 (0%)	0/101 (0%)	0/101 (0%)	0/101 (0%)	0/101 (0%)	0/101 (0%)	0/101 (0%)
Monthly Dosing [2][3]									
Dosing = 0%	1/101 (1%)	2/101 (2%)	11/101 (11%)	15/101 (15%)	19/101 (19%)	23/101 (23%)	25/101 (25%)	28/101 (28%)	27/101 (27%)
Dosing >= 25%	100/101 (99%)	96/101 (95%)	90/101 (89%)	84/101 (83%)	82/101 (81%)	77/101 (76%)	74/101 (73%)	73/101 (72%)	74/101 (73%)
Dosing >= 50%	98/101 (97%)	93/101 (92%)	86/101 (85%)	84/101 (83%)	82/101 (81%)	77/101 (76%)	72/101 (71%)	73/101 (72%)	73/101 (72%)
Dosing >= 75%	97/101 (96%)	90/101 (89%)	81/101 (80%)	81/101 (80%)	78/101 (77%)	76/101 (75%)	71/101 (70%)	69/101 (68%)	67/101 (66%)
Dosing = 100%	75/101 (74%)	59/101 (58%)	55/101 (54%)	51/101 (50%)	46/101 (46%)	51/101 (50%)	45/101 (45%)	46/101 (46%)	48/101 (48%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100
Cumulative Dosing									
Dosing = 0%	1/101 (1%)	1/101 (1%)	1/101 (1%)	1/101 (1%)	1/101 (1%)	1/101 (1%)	1/101 (1%)	1/101 (1%)	1/101 (1%)
Dosing >= 25%	100/101 (99%)	100/101 (99%)	99/101 (98%)	99/101 (98%)	97/101 (96%)	95/101 (94%)	91/101 (90%)	91/101 (90%)	87/101 (86%)
Dosing >= 50%	98/101 (97%)	97/101 (96%)	94/101 (93%)	90/101 (89%)	85/101 (84%)	83/101 (82%)	83/101 (82%)	81/101 (80%)	79/101 (78%)
Dosing >= 75%	97/101 (96%)	91/101 (90%)	86/101 (85%)	82/101 (81%)	82/101 (81%)	79/101 (78%)	76/101 (75%)	73/101 (72%)	73/101 (72%)
Dosing = 100%	75/101 (74%)	50/101 (50%)	36/101 (36%)	26/101 (26%)	17/101 (17%)	14/101 (14%)	12/101 (12%)	8/101 (8%)	8/101 (8%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100
Average Daily Dose (mg) for Days with Drug Coverage									
N	100	99	90	86	82	78	76	73	74
Mean (SD)	14 (3.8)	13 (3.1)	13 (3.3)	12 (3.4)	12 (3.5)	12 (3.5)	11 (3.5)	11 (3.5)	11 (3.6)
Median	15	14	14	12	12	12	12	12	12
Min, Max	4, 26	3, 18	3, 16	3, 17	3, 17	3, 17	3, 16	3, 16	3, 17
Q1, Q3	12, 16	12, 16	10, 16	10, 16	10, 14	10, 15	9, 14	9, 14	8, 14

[1] Participants are considered as missing if all CRFs of the 4-week period were not received.

[2] Percentages of dosing for the participants who were re-induced are based on the remainder number of days after induction in that period.

[3] Percentages of dosing for the participants who were terminated early are calculated up to the day before termination in that period.

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2a4 – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Chiang Mai, Thailand
Long Term Medication Assisted Treatment**

	Weeks Since Induction		
	Weeks 37–40	Weeks 41–44	Weeks 45–48
N Expected	101	101	101
Missing [1]	0 (0%)	0 (0%)	0 (0%)
Evaluated	101 (100%)	101 (100%)	101 (100%)
Re-induction [2]	2/101 (2%)	3/101 (3%)	0/101 (0%)
Termination [3]	0/101 (0%)	0/101 (0%)	0/101 (0%)
Monthly Dosing [2][3]			
Dosing = 0%	33/101 (33%)	33/101 (33%)	34/101 (34%)
Dosing >= 25%	67/101 (66%)	68/101 (67%)	65/101 (64%)
Dosing >= 50%	67/101 (66%)	67/101 (66%)	63/101 (62%)
Dosing >= 75%	65/101 (64%)	66/101 (65%)	61/101 (60%)
Dosing = 100%	43/101 (43%)	42/101 (42%)	39/101 (39%)
Min, Max	0, 100	0, 100	0, 100
Cumulative Dosing			
Dosing = 0%	1/101 (1%)	1/101 (1%)	1/101 (1%)
Dosing >= 25%	86/101 (85%)	84/101 (83%)	84/101 (83%)
Dosing >= 50%	78/101 (77%)	76/101 (75%)	76/101 (75%)
Dosing >= 75%	70/101 (69%)	67/101 (66%)	65/101 (64%)
Dosing = 100%	7/101 (7%)	4/101 (4%)	3/101 (3%)
Min, Max	0, 100	0, 100	0, 100
Average Daily Dose (mg) for Days with Drug Coverage			
N	68	68	67
Mean (SD)	11 (3.5)	11 (3.7)	10 (3.4)
Median	12	12	11
Min, Max	3, 16	2, 16	2, 16
Q1, Q3	9, 14	9, 14	7, 13
[1] Participants are considered as missing if all CRFs of the 4-week period were not received.			
[2] Percentages of dosing for the participants who were re-induced are based on the remainder number of days after induction in that period.			
[3] Percentages of dosing for the participants who were terminated early are calculated up to the day before termination in that period.			

HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2b1 – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Heng County, China
Long Term Medication Assisted Treatment
(Excluding Incarcerated Participants)

	Weeks Since Induction								
	Weeks 1–4	Weeks 5–8	Weeks 9–12	Weeks 13–16	Weeks 17–20	Weeks 21–24	Weeks 25–28	Weeks 29–32	Weeks 33–36
N Expected	205	205	205	205	204	204	204	204	203
Missing [1]	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Incarceration [4]	0 (0%)	1 (<1%)	2 (1%)	4 (2%)	6 (3%)	6 (3%)	6 (3%)	7 (3%)	9 (4%)
Evaluated	205 (100%)	204 (100%)	203 (99%)	201 (98%)	198 (97%)	198 (97%)	198 (97%)	197 (97%)	194 (96%)
Re-induction [2]	4/205 (2%)	3/204 (1%)	9/203 (4%)	4/201 (2%)	5/198 (3%)	13/198 (7%)	6/198 (3%)	8/197 (4%)	5/194 (3%)
Termination [3]	0/205 (0%)	0/204 (0%)	0/203 (0%)	1/201 (<1%)	0/198 (0%)	0/198 (0%)	0/198 (0%)	1/197 (1%)	0/194 (0%)
Monthly Dosing [2][3]									
Dosing = 0%	6/205 (3%)	16/204 (8%)	36/203 (18%)	52/201 (26%)	59/198 (30%)	52/198 (26%)	55/198 (28%)	69/197 (35%)	75/194 (39%)
Dosing >= 25%	191/205 (93%)	183/204 (90%)	162/203 (80%)	144/201 (72%)	137/198 (69%)	143/198 (72%)	134/198 (68%)	123/197 (62%)	113/194 (58%)
Dosing >= 50%	181/205 (88%)	170/204 (83%)	150/203 (74%)	133/201 (66%)	129/198 (65%)	134/198 (68%)	124/198 (63%)	118/197 (60%)	111/194 (57%)
Dosing >= 75%	173/205 (84%)	149/204 (73%)	136/203 (67%)	115/201 (57%)	115/198 (58%)	117/198 (59%)	109/198 (55%)	101/197 (51%)	102/194 (53%)
Dosing = 100%	126/205 (61%)	97/204 (48%)	82/203 (40%)	75/201 (37%)	67/198 (34%)	79/198 (40%)	64/198 (32%)	64/197 (32%)	65/194 (34%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100
Cumulative Dosing									
Dosing = 0%	6/205 (3%)	6/204 (3%)	6/203 (3%)	6/201 (3%)	6/198 (3%)	5/198 (3%)	5/198 (3%)	5/197 (3%)	5/194 (3%)
Dosing >= 25%	191/205 (93%)	187/204 (92%)	184/203 (91%)	180/201 (90%)	172/198 (87%)	171/198 (86%)	170/198 (86%)	166/197 (84%)	160/194 (82%)
Dosing >= 50%	181/205 (88%)	179/204 (88%)	169/203 (83%)	159/201 (79%)	146/198 (74%)	140/198 (71%)	138/198 (70%)	138/197 (70%)	135/194 (70%)
Dosing >= 75%	173/205 (84%)	155/204 (76%)	144/203 (71%)	131/201 (65%)	128/198 (65%)	122/198 (62%)	116/198 (59%)	110/197 (56%)	103/194 (53%)
Dosing = 100%	126/205 (61%)	81/204 (40%)	63/203 (31%)	48/201 (24%)	37/198 (19%)	29/198 (15%)	24/198 (12%)	18/197 (9%)	16/194 (8%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100
Average Daily Dose (mg) for Days with Drug Coverage									
N	199	188	167	149	139	146	143	128	119
Mean (SD)	14 (3.2)	13 (2.9)	13 (2.8)	12 (2.7)	12 (2.9)	12 (2.8)	11 (3.0)	11 (3.0)	11 (2.8)
Median	15	14	12	12	12	12	12	12	12
Min, Max	4, 24	4, 20	4, 17	4, 17	4, 18	4, 16	5, 18	4, 16	4, 16
Q1, Q3	12, 16	12, 16	10, 16	10, 14	10, 14	10, 14	8, 14	8, 14	8, 12

[1] Participants are considered as missing if all CRFs of the 4-week period were not received.

[2] Percentages of dosing for the participants who were re-induced are based on the remainder number of days after induction in that period.

[3] Percentages of dosing for the participants who were terminated early are calculated up to the day before termination in that period.

[4] Participants who were incarcerated for the whole four weeks are excluded.

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2b1 – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Heng County, China
Long Term Medication Assisted Treatment
(Excluding Incarcerated Participants)**

	Weeks Since Induction		
	Weeks 37–40	Weeks 41–44	Weeks 45–48
N Expected	203	203	200
Missing [1]	0 (0%)	0 (0%)	0 (0%)
Incarceration [4]	11 (5%)	12 (6%)	16 (8%)
Evaluated	192 (95%)	191 (94%)	184 (92%)
Re-induction [2]	8/192 (4%)	10/191 (5%)	2/184 (1%)
Termination [3]	0/192 (0%)	3/191 (2%)	6/184 (3%)
Monthly Dosing [2][3]			
Dosing = 0%	75/192 (39%)	72/191 (38%)	80/184 (43%)
Dosing >= 25%	115/192 (60%)	113/191 (59%)	102/184 (55%)
Dosing >= 50%	107/192 (56%)	106/191 (55%)	96/184 (52%)
Dosing >= 75%	98/192 (51%)	98/191 (51%)	84/184 (46%)
Dosing = 100%	63/192 (33%)	61/191 (32%)	55/184 (30%)
Min, Max	0, 100	0, 100	0, 100
Cumulative Dosing			
Dosing = 0%	4/192 (2%)	4/191 (2%)	4/184 (2%)
Dosing >= 25%	156/192 (81%)	152/191 (80%)	147/184 (80%)
Dosing >= 50%	132/192 (69%)	128/191 (67%)	122/184 (66%)
Dosing >= 75%	101/192 (53%)	96/191 (50%)	92/184 (50%)
Dosing = 100%	9/192 (5%)	8/191 (4%)	7/184 (4%)
Min, Max	0, 100	0, 100	0, 100
Average Daily Dose (mg) for Days with Drug Coverage			
N	117	119	104
Mean (SD)	10 (2.8)	10 (3.1)	9 (2.8)
Median	10	10	9
Min, Max	4, 17	3, 16	2, 15
Q1, Q3	8, 12	8, 12	7, 11

[1] Participants are considered as missing if all CRFs of the 4-week period were not received.

[2] Percentages of dosing for the participants who were re-induced are based on the remainder number of days after induction in that period.

[3] Percentages of dosing for the participants who were terminated early are calculated up to the day before termination in that period.

[4] Participants who were incarcerated for the whole four weeks are excluded.

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2b2 – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Nanning, China
Long Term Medication Assisted Treatment
(Excluding Incarcerated Participants)**

	Weeks Since Induction								
	Weeks 1–4	Weeks 5–8	Weeks 9–12	Weeks 13–16	Weeks 17–20	Weeks 21–24	Weeks 25–28	Weeks 29–32	Weeks 33–36
N Expected	79	79	79	79	79	79	79	79	79
Missing [1]	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Incarceration [4]	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Evaluated	79 (100%)	79 (100%)	79 (100%)	79 (100%)	79 (100%)	79 (100%)	79 (100%)	79 (100%)	79 (100%)
Re-induction [2]	0/79 (0%)	1/79 (1%)	3/79 (4%)	0/79 (0%)	1/79 (1%)	4/79 (5%)	3/79 (4%)	1/79 (1%)	1/79 (1%)
Termination [3]	0/79 (0%)	0/79 (0%)	0/79 (0%)	0/79 (0%)	0/79 (0%)	0/79 (0%)	0/79 (0%)	0/79 (0%)	0/79 (0%)
Monthly Dosing [2][3]									
Dosing = 0%	8/79 (10%)	11/79 (14%)	14/79 (18%)	19/79 (24%)	22/79 (28%)	23/79 (29%)	25/79 (32%)	31/79 (39%)	34/79 (43%)
Dosing >= 25%	70/79 (89%)	67/79 (85%)	63/79 (80%)	59/79 (75%)	56/79 (71%)	55/79 (70%)	53/79 (67%)	47/79 (59%)	44/79 (56%)
Dosing >= 50%	69/79 (87%)	62/79 (78%)	61/79 (77%)	58/79 (73%)	54/79 (68%)	54/79 (68%)	49/79 (62%)	46/79 (58%)	44/79 (56%)
Dosing >= 75%	66/79 (84%)	61/79 (77%)	57/79 (72%)	56/79 (71%)	51/79 (65%)	50/79 (63%)	44/79 (56%)	42/79 (53%)	41/79 (52%)
Dosing = 100%	56/79 (71%)	41/79 (52%)	44/79 (56%)	43/79 (54%)	36/79 (46%)	39/79 (49%)	28/79 (35%)	30/79 (38%)	29/79 (37%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100
Cumulative Dosing									
Dosing = 0%	8/79 (10%)	7/79 (9%)	7/79 (9%)	7/79 (9%)	7/79 (9%)	7/79 (9%)	7/79 (9%)	7/79 (9%)	7/79 (9%)
Dosing >= 25%	70/79 (89%)	70/79 (89%)	68/79 (86%)	65/79 (82%)	64/79 (81%)	63/79 (80%)	63/79 (80%)	63/79 (80%)	61/79 (77%)
Dosing >= 50%	69/79 (87%)	65/79 (82%)	63/79 (80%)	63/79 (80%)	61/79 (77%)	58/79 (73%)	57/79 (72%)	56/79 (71%)	56/79 (71%)
Dosing >= 75%	66/79 (84%)	61/79 (77%)	61/79 (77%)	58/79 (73%)	55/79 (70%)	54/79 (68%)	51/79 (65%)	50/79 (63%)	46/79 (58%)
Dosing = 100%	56/79 (71%)	41/79 (52%)	38/79 (48%)	31/79 (39%)	26/79 (33%)	23/79 (29%)	18/79 (23%)	15/79 (19%)	13/79 (16%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100
Average Daily Dose (mg) for Days with Drug Coverage									
N	71	68	65	60	57	56	54	48	45
Mean (SD)	17 (3.8)	15 (2.9)	14 (3.5)	13 (3.6)	13 (3.6)	13 (3.9)	13 (4.1)	12 (4.1)	13 (3.4)
Median	18	16	16	16	15	14	15	13	12
Min, Max	2, 23	1, 20	1, 18	1, 16	2, 16	2, 21	2, 20	2, 16	4, 16
Q1, Q3	17, 20	14, 16	12, 16	10, 16	11, 16	10, 16	10, 16	10, 16	10, 16

[1] Participants are considered as missing if all CRFs of the 4-week period were not received.

[2] Percentages of dosing for the participants who were re-induced are based on the remainder number of days after induction in that period.

[3] Percentages of dosing for the participants who were terminated early are calculated up to the day before termination in that period.

[4] Participants who were incarcerated for the whole four weeks are excluded.

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2b2 – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Nanning, China
Long Term Medication Assisted Treatment
(Excluding Incarcerated Participants)**

	Weeks Since Induction		
	Weeks 37–40	Weeks 41–44	Weeks 45–48
N Expected	79	78	77
Missing [1]	0 (0%)	0 (0%)	0 (0%)
Incarceration [4]	0 (0%)	0 (0%)	0 (0%)
Evaluated	79 (100%)	78 (100%)	77 (100%)
Re-induction [2]	1/79 (1%)	2/78 (3%)	1/77 (1%)
Termination [3]	1/79 (1%)	1/78 (1%)	3/77 (4%)
Monthly Dosing [2][3]			
Dosing = 0%	34/79 (43%)	33/78 (42%)	36/77 (47%)
Dosing >= 25%	45/79 (57%)	45/78 (58%)	38/77 (49%)
Dosing >= 50%	45/79 (57%)	42/78 (54%)	37/77 (48%)
Dosing >= 75%	42/79 (53%)	39/78 (50%)	33/77 (43%)
Dosing = 100%	21/79 (27%)	22/78 (28%)	19/77 (25%)
Min, Max	0, 100	0, 100	0, 100
Cumulative Dosing			
Dosing = 0%	7/79 (9%)	6/78 (8%)	5/77 (6%)
Dosing >= 25%	60/79 (76%)	59/78 (76%)	58/77 (75%)
Dosing >= 50%	55/79 (70%)	55/78 (71%)	50/77 (65%)
Dosing >= 75%	44/79 (56%)	44/78 (56%)	43/77 (56%)
Dosing = 100%	9/79 (11%)	8/78 (10%)	5/77 (6%)
Min, Max	0, 100	0, 100	0, 100
Average Daily Dose (mg) for Days with Drug Coverage			
N	45	45	41
Mean (SD)	13 (3.5)	13 (3.4)	11 (3.3)
Median	12	13	11
Min, Max	5, 23	5, 20	1, 16
Q1, Q3	12, 16	12, 16	9, 13

[1] Participants are considered as missing if all CRFs of the 4-week period were not received.

[2] Percentages of dosing for the participants who were re-induced are based on the remainder number of days after induction in that period.

[3] Percentages of dosing for the participants who were terminated early are calculated up to the day before termination in that period.

[4] Participants who were incarcerated for the whole four weeks are excluded.

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2b3 – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Xinjiang, China
Long Term Medication Assisted Treatment
(Excluding Incarcerated Participants)**

	Weeks Since Induction								
	Weeks 1–4	Weeks 5–8	Weeks 9–12	Weeks 13–16	Weeks 17–20	Weeks 21–24	Weeks 25–28	Weeks 29–32	Weeks 33–36
N Expected	239	239	239	239	239	238	238	238	238
Missing [1]	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Incarceration [4]	0 (0%)	4 (2%)	8 (3%)	12 (5%)	11 (5%)	14 (6%)	15 (6%)	21 (9%)	23 (10%)
Evaluated	239 (100%)	235 (98%)	231 (97%)	227 (95%)	228 (95%)	224 (94%)	223 (94%)	217 (91%)	215 (90%)
Re-induction [2]	2/239 (1%)	6/235 (3%)	11/231 (5%)	9/227 (4%)	17/228 (7%)	24/224 (11%)	17/223 (8%)	26/217 (12%)	7/215 (3%)
Termination [3]	0/239 (0%)	0/235 (0%)	0/231 (0%)	0/227 (0%)	1/228 (<1%)	0/224 (0%)	0/223 (0%)	0/217 (0%)	0/215 (0%)
Monthly Dosing [2][3]									
Dosing = 0%	9/239 (4%)	19/235 (8%)	41/231 (18%)	48/227 (21%)	64/228 (28%)	62/224 (28%)	68/223 (30%)	67/217 (31%)	73/215 (34%)
Dosing >= 25%	221/239 (92%)	199/235 (85%)	181/231 (78%)	169/227 (74%)	154/228 (68%)	152/224 (68%)	147/223 (66%)	141/217 (65%)	137/215 (64%)
Dosing >= 50%	207/239 (87%)	180/235 (77%)	162/231 (70%)	145/227 (64%)	142/228 (62%)	132/224 (59%)	133/223 (60%)	123/217 (57%)	124/215 (58%)
Dosing >= 75%	190/239 (79%)	157/235 (67%)	141/231 (61%)	119/227 (52%)	109/228 (48%)	115/224 (51%)	107/223 (48%)	108/217 (50%)	103/215 (48%)
Dosing = 100%	118/239 (49%)	84/235 (36%)	67/231 (29%)	63/227 (28%)	51/228 (22%)	54/224 (24%)	52/223 (23%)	56/217 (26%)	50/215 (23%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100
Cumulative Dosing									
Dosing = 0%	9/239 (4%)	8/235 (3%)	8/231 (3%)	7/227 (3%)	6/228 (3%)	5/224 (2%)	5/223 (2%)	4/217 (2%)	4/215 (2%)
Dosing >= 25%	221/239 (92%)	215/235 (91%)	208/231 (90%)	197/227 (87%)	194/228 (85%)	187/224 (83%)	183/223 (82%)	178/217 (82%)	174/215 (81%)
Dosing >= 50%	207/239 (87%)	192/235 (82%)	183/231 (79%)	174/227 (77%)	161/228 (71%)	154/224 (69%)	149/223 (67%)	144/217 (66%)	138/215 (64%)
Dosing >= 75%	190/239 (79%)	162/235 (69%)	147/231 (64%)	131/227 (58%)	121/228 (53%)	112/224 (50%)	108/223 (48%)	99/217 (46%)	99/215 (46%)
Dosing = 100%	118/239 (49%)	73/235 (31%)	43/231 (19%)	27/227 (12%)	18/228 (8%)	17/224 (8%)	11/223 (5%)	9/217 (4%)	9/215 (4%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100
Average Daily Dose (mg) for Days with Drug Coverage									
N	230	216	190	179	164	162	155	150	142
Mean (SD)	18 (4.4)	14 (3.6)	12 (3.9)	12 (4.0)	11 (4.4)	11 (4.4)	11 (3.8)	11 (4.7)	11 (4.5)
Median	18	15	13	12	12	11	11	11	10
Min, Max	2, 32	2, 32	2, 26	2, 28	1, 25	1, 25	1, 20	2, 26	2, 24
Q1, Q3	16, 20	11, 16	10, 15	9, 15	8, 14	8, 14	8, 14	7, 14	7, 14

[1] Participants are considered as missing if all CRFs of the 4-week period were not received.

[2] Percentages of dosing for the participants who were re-induced are based on the remainder number of days after induction in that period.

[3] Percentages of dosing for the participants who were terminated early are calculated up to the day before termination in that period.

[4] Participants who were incarcerated for the whole four weeks are excluded.

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2b3 – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Xinjiang, China
Long Term Medication Assisted Treatment
(Excluding Incarcerated Participants)**

	Weeks Since Induction		
	Weeks 37–40	Weeks 41–44	Weeks 45–48
N Expected	238	237	234
Missing [1]	0 (0%)	0 (0%)	0 (0%)
Incarceration [4]	26 (11%)	27 (11%)	29 (12%)
Evaluated	212 (89%)	210 (89%)	205 (88%)
Re-induction [2]	11/212 (5%)	16/210 (8%)	4/205 (2%)
Termination [3]	1/212 (<1%)	3/210 (1%)	6/205 (3%)
Monthly Dosing [2][3]			
Dosing = 0%	79/212 (37%)	78/210 (37%)	87/205 (42%)
Dosing >= 25%	126/212 (59%)	125/210 (60%)	110/205 (54%)
Dosing >= 50%	116/212 (55%)	107/210 (51%)	97/205 (47%)
Dosing >= 75%	99/212 (47%)	92/210 (44%)	80/205 (39%)
Dosing = 100%	48/212 (23%)	45/210 (21%)	40/205 (20%)
Min, Max	0, 100	0, 100	0, 100
Cumulative Dosing			
Dosing = 0%	4/212 (2%)	4/210 (2%)	4/205 (2%)
Dosing >= 25%	169/212 (80%)	166/210 (79%)	161/205 (79%)
Dosing >= 50%	132/212 (62%)	124/210 (59%)	117/205 (57%)
Dosing >= 75%	95/212 (45%)	93/210 (44%)	87/205 (42%)
Dosing = 100%	8/212 (4%)	6/210 (3%)	5/205 (2%)
Min, Max	0, 100	0, 100	0, 100
Average Daily Dose (mg) for Days with Drug Coverage			
N	133	132	118
Mean (SD)	10 (4.5)	10 (5.0)	9 (4.5)
Median	11	11	9
Min, Max	2, 17	1, 32	2, 28
Q1, Q3	7, 15	6, 14	5, 12

[1] Participants are considered as missing if all CRFs of the 4-week period were not received.

[2] Percentages of dosing for the participants who were re-induced are based on the remainder number of days after induction in that period.

[3] Percentages of dosing for the participants who were terminated early are calculated up to the day before termination in that period.

[4] Participants who were incarcerated for the whole four weeks are excluded.

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2b4 – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Chiang Mai, Thailand
Long Term Medication Assisted Treatment
(Excluding Incarcerated Participants)**

	Weeks Since Induction								
	Weeks 1–4	Weeks 5–8	Weeks 9–12	Weeks 13–16	Weeks 17–20	Weeks 21–24	Weeks 25–28	Weeks 29–32	Weeks 33–36
N Expected	101	101	101	101	101	101	101	101	101
Missing [1]	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Incarceration [4]	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	2 (2%)	1 (1%)
Evaluated	101 (100%)	101 (100%)	101 (100%)	101 (100%)	101 (100%)	100 (99%)	100 (99%)	99 (98%)	100 (99%)
Re-induction [2]	2/101 (2%)	5/101 (5%)	2/101 (2%)	3/101 (3%)	1/101 (1%)	3/100 (3%)	0/100 (0%)	4/99 (4%)	3/100 (3%)
Termination [3]	0/101 (0%)	0/101 (0%)	0/101 (0%)	0/101 (0%)	0/101 (0%)	0/100 (0%)	0/100 (0%)	0/99 (0%)	0/100 (0%)
Monthly Dosing [2][3]									
Dosing = 0%	1/101 (1%)	2/101 (2%)	11/101 (11%)	15/101 (15%)	19/101 (19%)	22/100 (22%)	24/100 (24%)	26/99 (26%)	26/100 (26%)
Dosing >= 25%	100/101 (99%)	96/101 (95%)	90/101 (89%)	84/101 (83%)	82/101 (81%)	77/100 (77%)	74/100 (74%)	73/99 (74%)	74/100 (74%)
Dosing >= 50%	98/101 (97%)	93/101 (92%)	86/101 (85%)	84/101 (83%)	82/101 (81%)	77/100 (77%)	72/100 (72%)	73/99 (74%)	73/100 (73%)
Dosing >= 75%	97/101 (96%)	90/101 (89%)	81/101 (80%)	81/101 (80%)	78/101 (77%)	76/100 (76%)	71/100 (71%)	69/99 (70%)	67/100 (67%)
Dosing = 100%	75/101 (74%)	59/101 (58%)	55/101 (54%)	51/101 (50%)	46/101 (46%)	51/100 (51%)	45/100 (45%)	46/99 (46%)	48/100 (48%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100
Cumulative Dosing									
Dosing = 0%	1/101 (1%)	1/101 (1%)	1/101 (1%)	1/101 (1%)	1/101 (1%)	1/100 (1%)	1/100 (1%)	1/99 (1%)	1/100 (1%)
Dosing >= 25%	100/101 (99%)	100/101 (99%)	99/101 (98%)	99/101 (98%)	97/101 (96%)	94/100 (94%)	90/100 (90%)	89/99 (90%)	86/100 (86%)
Dosing >= 50%	98/101 (97%)	97/101 (96%)	94/101 (93%)	90/101 (89%)	85/101 (84%)	82/100 (82%)	82/100 (82%)	79/99 (80%)	79/100 (79%)
Dosing >= 75%	97/101 (96%)	91/101 (90%)	86/101 (85%)	82/101 (81%)	82/101 (81%)	79/100 (79%)	76/100 (76%)	73/99 (74%)	73/100 (73%)
Dosing = 100%	75/101 (74%)	50/101 (50%)	36/101 (36%)	26/101 (26%)	17/101 (17%)	14/100 (14%)	12/100 (12%)	8/99 (8%)	8/100 (8%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100	0, 100
Average Daily Dose (mg) for Days with Drug Coverage									
N	100	99	90	86	82	78	76	73	74
Mean (SD)	14 (3.8)	13 (3.1)	13 (3.3)	12 (3.4)	12 (3.5)	12 (3.5)	11 (3.5)	11 (3.5)	11 (3.6)
Median	15	14	14	12	12	12	12	12	12
Min, Max	4, 26	3, 18	3, 16	3, 17	3, 17	3, 17	3, 16	3, 16	3, 17
Q1, Q3	12, 16	12, 16	10, 16	10, 16	10, 14	10, 15	9, 14	9, 14	8, 14

[1] Participants are considered as missing if all CRFs of the 4-week period were not received.

[2] Percentages of dosing for the participants who were re-induced are based on the remainder number of days after induction in that period.

[3] Percentages of dosing for the participants who were terminated early are calculated up to the day before termination in that period.

[4] Participants who were incarcerated for the whole four weeks are excluded.

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2b4 – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Chiang Mai, Thailand
Long Term Medication Assisted Treatment
(Excluding Incarcerated Participants)**

	Weeks Since Induction		
	Weeks 37–40	Weeks 41–44	Weeks 45–48
N Expected	101	101	101
Missing [1]	0 (0%)	0 (0%)	0 (0%)
Incarceration [4]	3 (3%)	2 (2%)	2 (2%)
Evaluated	98 (97%)	99 (98%)	99 (98%)
Re-induction [2]	2/98 (2%)	3/99 (3%)	0/99 (0%)
Termination [3]	0/98 (0%)	0/99 (0%)	0/99 (0%)
Monthly Dosing [2][3]			
Dosing = 0%	30/98 (31%)	31/99 (31%)	32/99 (32%)
Dosing >= 25%	67/98 (68%)	68/99 (69%)	65/99 (66%)
Dosing >= 50%	67/98 (68%)	67/99 (68%)	63/99 (64%)
Dosing >= 75%	65/98 (66%)	66/99 (67%)	61/99 (62%)
Dosing = 100%	43/98 (44%)	42/99 (42%)	39/99 (39%)
Min, Max	0, 100	0, 100	0, 100
Cumulative Dosing			
Dosing = 0%	1/98 (1%)	1/99 (1%)	1/99 (1%)
Dosing >= 25%	84/98 (86%)	82/99 (83%)	82/99 (83%)
Dosing >= 50%	77/98 (79%)	75/99 (76%)	75/99 (76%)
Dosing >= 75%	69/98 (70%)	67/99 (68%)	65/99 (66%)
Dosing = 100%	7/98 (7%)	4/99 (4%)	3/99 (3%)
Min, Max	0, 100	0, 100	0, 100
Average Daily Dose (mg) for Days with Drug Coverage			
N	68	68	67
Mean (SD)	11 (3.5)	11 (3.7)	10 (3.4)
Median	12	12	11
Min, Max	3, 16	2, 16	2, 16
Q1, Q3	9, 14	9, 14	7, 13

[1] Participants are considered as missing if all CRFs of the 4-week period were not received.

[2] Percentages of dosing for the participants who were re-induced are based on the remainder number of days after induction in that period.

[3] Percentages of dosing for the participants who were terminated early are calculated up to the day before termination in that period.

[4] Participants who were incarcerated for the whole four weeks are excluded.

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 2c – Post-induction Dosing of Suboxone (Buprenorphine/Naloxone), by Site
Short Term Medication Assisted Treatment**

	Heng County China	Nanning China	Xinjiang China	Chiang Mai Thailand	Total
Enrollment (Short Term Medication Assisted Treatment)	206	82	239	101	628
Initial detoxification [1][2][3]					
complete (full adherence)	130/206 (63%)	62/81 (77%)	134/239 (56%)	96/101 (95%)	422/627 (67%)
complete (partial adherence)	52/206 (25%)	7/81 (9%)	59/239 (25%)	2/101 (2%)	120/627 (19%)
incomplete	24/206 (12%)	12/81 (15%)	46/239 (19%)	3/101 (3%)	85/627 (14%)
Max dosing summary (mg) [1][4]					
0–8	17/206 (8%)	8/81 (10%)	29/239 (12%)	8/101 (8%)	62/627 (10%)
9–16	127/206 (62%)	26/81 (32%)	55/239 (23%)	66/101 (65%)	274/627 (44%)
17–24	61/206 (30%)	45/81 (56%)	129/239 (54%)	18/101 (18%)	253/627 (40%)
25–32	1/206 (<1%)	2/81 (2%)	26/239 (11%)	9/101 (9%)	38/627 (6%)
33–40	0/206 (0%)	0/81 (0%)	0/239 (0%)	0/101 (0%)	0/627 (0%)
% completed planned dosing [1][5]					
0	11/206 (5%)	10/81 (12%)	27/239 (11%)	2/101 (2%)	50/627 (8%)
0 < % <= 20	0/206 (0%)	0/81 (0%)	2/239 (1%)	0/101 (0%)	2/627 (<1%)
20 < % <= 40	4/206 (2%)	1/81 (1%)	4/239 (2%)	0/101 (0%)	9/627 (1%)
40 < % <= 60	3/206 (1%)	1/81 (1%)	4/239 (2%)	1/101 (1%)	9/627 (1%)
60 < % <= 80	5/206 (2%)	0/81 (0%)	2/239 (1%)	0/101 (0%)	7/627 (1%)
80 < % < 100	1/206 (<1%)	0/81 (0%)	4/239 (2%)	0/101 (0%)	5/627 (1%)
100	182/206 (88%)	69/81 (85%)	196/239 (82%)	98/101 (97%)	545/627 (87%)

[1] Participants who are still in the process of detoxification are not reported.

[2] Participants are considered 'complete' if they either are tapering to a zero mg dose or reach the last planned dosing visit according to the total dose at the 3rd day of induction. Otherwise, they are considered 'incomplete'.


[3] Participants who completed the detoxification process are considered 'fully adherent' if they didn't miss any dosing visit. Otherwise, they are considered 'partially adherent'.

[4] Max dosing is the last dosage participants received during the induction.

[5] % completed planned dosing is the ratio of the total dosage taken to the total dosage expected.


HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
 Adherence Report – September 10, 2012
 Visit Cutoff Date: September 9, 2012

Figure 1a1 – Monthly Post-induction Dosing of Suboxone in Long Term Medication Assisted Treatment Arm, by Site
 Heng County, China




HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
 Adherence Report – September 10, 2012
 Visit Cutoff Date: September 9, 2012

Figure 1a2 – Monthly Post-induction Dosing of Suboxone in Long Term Medication Assisted Treatment Arm, by Site
 Nanning, China



HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
 Adherence Report – September 10, 2012
 Visit Cutoff Date: September 9, 2012

Figure 1a3 – Monthly Post-induction Dosing of Suboxone in Long Term Medication Assisted Treatment Arm, by Site
 Xinjiang, China




HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention

Adherence Report – September 10, 2012

Visit Cutoff Date: September 9, 2012

Figure 1a4 – Monthly Post-induction Dosing of Suboxone in Long Term Medication Assisted Treatment Arm, by Site
Chiang Mai, Thailand




HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention

Adherence Report – September 10, 2012

Visit Cutoff Date: September 9, 2012

Figure 1b1 – Monthly Post-induction Dosing of Suboxone in Long Term Medication Assisted Treatment Arm, by Site
Heng County, China
(Excluding Incarcerated Participants)




HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention

Adherence Report – September 10, 2012

Visit Cutoff Date: September 9, 2012

Figure 1b2 – Monthly Post-induction Dosing of Suboxone in Long Term Medication Assisted Treatment Arm, by Site
Nanning, China
(Excluding Incarcerated Participants)




HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention

Adherence Report – September 10, 2012

Visit Cutoff Date: September 9, 2012

Figure 1b3 – Monthly Post-induction Dosing of Suboxone in Long Term Medication Assisted Treatment Arm, by Site
Xinjiang, China
(Excluding Incarcerated Participants)




HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention

Adherence Report – September 10, 2012


Visit Cutoff Date: September 9, 2012

Figure 1b4 – Monthly Post-induction Dosing of Suboxone in Long Term Medication Assisted Treatment Arm, by Site
Chiang Mai, Thailand
(Excluding Incarcerated Participants)




HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
 Adherence Report – September 10, 2012
 Visit Cutoff Date: September 9, 2012

Figure 2a – Average Daily Dose of Post-induction Dosing of Suboxone in Long Term Medication Assisted Treatment Arm, by Site
 Heng County, China




HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
 Adherence Report – September 10, 2012
 Visit Cutoff Date: September 9, 2012

Figure 2b – Average Daily Dose of Post-induction Dosing of Suboxone in Long Term Medication Assisted Treatment Arm, by Site
 Nanning, China




HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
 Adherence Report – September 10, 2012
 Visit Cutoff Date: September 9, 2012

Figure 2c – Average Daily Dose of Post-induction Dosing of Suboxone in Long Term Medication Assisted Treatment Arm, by Site
 Xinjiang, China



HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
 Adherence Report – September 10, 2012
 Visit Cutoff Date: September 9, 2012

Figure 2d – Average Daily Dose of Post-induction Dosing of Suboxone in Long Term Medication Assisted Treatment Arm, by Site
 Chiang Mai, Thailand



HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention

Adherence Report – September 10, 2012

Visit Cutoff Date: September 9, 2012

**Table 3a – Reason for Missing Entire Week of Dosing of Suboxone (Buprenorphine/Naloxone), by Site and by Arm
Long Term Medication Assisted Treatment**

	Heng County, China	Nanning, China	Xinjiang, China	Chiang Mai, Thailand	Total
Number Enrolled in Both Arms	411	161	478	202	1252
Number Enrolled in Long Term Medication Assisted Treatment Arm	205	79	239	101	624
Participants with One or More Week of Missed Dosing	165	54	186	52	457
Participant-based Reason*					
Reported incarceration	23/156 (15%)	0/10 (0%)	1/186 (1%)	2/48 (4%)	26/400 (7%)
Verified incarceration	21/156 (13%)	0/10 (0%)	53/186 (28%)	10/48 (21%)	84/400 (21%)
Participant refused	109/156 (70%)	9/10 (90%)	63/186 (34%)	27/48 (56%)	208/400 (52%)
Illness/hospitalization	0/156 (0%)	1/10 (10%)	4/186 (2%)	7/48 (15%)	12/400 (3%)
Relocation	0/156 (0%)	0/10 (0%)	0/186 (0%)	2/48 (4%)	2/400 (1%)
Personal obligation	131/156 (84%)	1/10 (10%)	143/186 (77%)	11/48 (23%)	286/400 (72%)
Unknown	35/156 (22%)	0/10 (0%)	49/186 (26%)	13/48 (27%)	97/400 (24%)
Other	2/156 (1%)	0/10 (0%)	0/186 (0%)	18/48 (38%)	20/400 (5%)
Protocol-specified Reason*					
Intoxication during drug dispensing visit	0/43 (0%)	–	–	0/29 (0%)	0/72 (0%)
Medication interfere with BUP/NX	0/43 (0%)	–	–	0/29 (0%)	0/72 (0%)
SAE related to study drug	0/43 (0%)	–	–	0/29 (0%)	0/72 (0%)
Pregnancy	0/43 (0%)	–	–	0/29 (0%)	0/72 (0%)
Enrollment in another study	0/43 (0%)	–	–	1/29 (3%)	1/72 (1%)
Hypersensitivity to BUP/NX	0/43 (0%)	–	–	1/29 (3%)	1/72 (1%)
Clinician or PSRT decision	0/43 (0%)	–	–	2/29 (7%)	2/72 (3%)
Other	37/43 (86%)	–	–	28/29 (97%)	65/72 (90%)
Other Reason *	75	48	14	0	137
Note: A participant may answer either participant-based reason, protocol-specified reason, or other reason at different visits.					

* Each week's missed visit reasons may differ for participants who missed visits more than one week.

HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention

Adherence Report – September 10, 2012

Visit Cutoff Date: September 9, 2012

**Table 3b – Reason for Missing Entire Week of Dosing of Suboxone (Buprenorphine/Naloxone), by Site and by Arm
Short Term Medication Assisted Treatment**

	Heng County, China	Nanning, China	Xinjiang, China	Chiang Mai, Thailand	Total
Number Enrolled in Both Arms	411	161	478	202	1252
Number Enrolled in Short Term Medication Assisted Treatment Arm	206	82	239	101	628
Participants with One or More Week of Missed Dosing	52	20	45	5	122
Participant-based Reason*					
Reported incarceration	2/36 (6%)	0/6 (0%)	0/45 (0%)	0/4 (0%)	2/91 (2%)
Verified incarceration	2/36 (6%)	0/6 (0%)	3/45 (7%)	0/4 (0%)	5/91 (5%)
Participant refused	21/36 (58%)	6/6 (100%)	17/45 (38%)	3/4 (75%)	47/91 (52%)
Illness/hospitalization	0/36 (0%)	0/6 (0%)	0/45 (0%)	0/4 (0%)	0/91 (0%)
Relocation	0/36 (0%)	0/6 (0%)	0/45 (0%)	0/4 (0%)	0/91 (0%)
Personal obligation	9/36 (25%)	0/6 (0%)	18/45 (40%)	1/4 (25%)	28/91 (31%)
Unknown	3/36 (8%)	0/6 (0%)	8/45 (18%)	0/4 (0%)	11/91 (12%)
Other	0/36 (0%)	0/6 (0%)	0/45 (0%)	0/4 (0%)	0/91 (0%)
Protocol-specified Reason*					
Intoxication during drug dispensing visit	0/1 (0%)	–	–	0/1 (0%)	0/2 (0%)
Medication interfere with BUP/NX	0/1 (0%)	–	–	0/1 (0%)	0/2 (0%)
SAE related to study drug	0/1 (0%)	–	–	0/1 (0%)	0/2 (0%)
Pregnancy	0/1 (0%)	–	–	0/1 (0%)	0/2 (0%)
Enrollment in another study	0/1 (0%)	–	–	0/1 (0%)	0/2 (0%)
Hypersensitivity to BUP/NX	0/1 (0%)	–	–	0/1 (0%)	0/2 (0%)
Clinician or PSRT decision	0/1 (0%)	–	–	0/1 (0%)	0/2 (0%)
Other	1/1 (100%)	–	–	1/1 (100%)	2/2 (100%)
Other Reason *	19	14	0	0	33
Note: A participant may answer either participant-based reason, protocol-specified reason, or other reason at different visits.					

* Each week's missed visit reasons may differ for participants who missed visits more than one week.

**HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 4a – Attendance at Weekly Counseling Session, by Site**

	Heng County, China	Nanning, China	Xinjiang, China	Chiang Mai, Thailand	Total
Number Enrolled	411	161	478	202	1252
N Expected	411	161	478	202	1252
Missing	0/411 (0%)	0/161 (0%)	0/478 (0%)	0/202 (0%)	0/1252 (0%)
Evaluated	411/411 (100%)	161/161 (100%)	478/478 (100%)	202/202 (100%)	1252/1252 (100%)
Attendance					
Attendance = 0%	3/411 (1%)	10/161 (6%)	8/478 (2%)	3/202 (1%)	24/1252 (2%)
Attendance >= 25%	387/411 (94%)	141/161 (88%)	444/478 (93%)	199/202 (99%)	1171/1252 (94%)
Attendance >= 50%	334/411 (81%)	122/161 (76%)	391/478 (82%)	188/202 (93%)	1035/1252 (83%)
Attendance >= 75%	270/411 (66%)	113/161 (70%)	348/478 (73%)	180/202 (89%)	911/1252 (73%)
Attendance = 100%	193/411 (47%)	85/161 (53%)	253/478 (53%)	126/202 (62%)	657/1252 (52%)
Min, Max	0, 100	0, 100	0, 100	0, 100	0, 100

Note : CRF is expected after the 12th weekly counseling session is completed.

HPTN 058 – Phase III Trial of Opiate Substitution Treatment as HIV Prevention
Adherence Report – September 10, 2012
Visit Cutoff Date: September 9, 2012
Table 4b – Attendance at Monthly Counseling Session, by Site

	Heng County, China	Nanning, China	Xinjiang, China	Chiang Mai, Thailand	Total
Number Enrolled	411	161	478	202	1252
N Expected	387	138	462	202	1189
Missing	1/387 (<1%)	0/138 (0%)	4/462 (1%)	0/202 (0%)	5/1189 (<1%)
Evaluated	386/387 (100%)	138/138 (100%)	458/462 (99%)	202/202 (100%)	1184/1189 (100%)
Attendance					
Attendance = 0%	38/386 (10%)	10/138 (7%)	38/458 (8%)	5/202 (2%)	91/1184 (8%)
Attendance >= 25%	317/386 (82%)	105/138 (76%)	384/458 (84%)	189/202 (94%)	995/1184 (84%)
Attendance >= 50%	268/386 (69%)	89/138 (64%)	344/458 (75%)	172/202 (85%)	873/1184 (74%)
Attendance >= 75%	212/386 (55%)	68/138 (49%)	276/458 (60%)	134/202 (66%)	690/1184 (58%)
Attendance = 100%	138/386 (36%)	35/138 (25%)	189/458 (41%)	86/202 (43%)	448/1184 (38%)
Min, Max	0, 120	0, 100	0, 100	0, 100	0, 120

Note : CRF is expected after the month 12 counseling session is completed.